Web Results

en.wikipedia.org/wiki/Miglustat

Miglustat (OGT 918, N-butyl-deoxynojirimycin) is a drug developed by Oxford GlycoSciences and marketed by Actelion and is used primarily to treat type I ...

www.drugbank.ca/drugs/DB00419

Miglustat is a drug used to treat Gaucher disease. ... Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C).

www.ncbi.nlm.nih.gov/pubmed/17689147

Miglustat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step of glycosphingolipid synthesis. Miglustat is ...

pubchem.ncbi.nlm.nih.gov/compound/Miglustat

SC-48334 is a synthetic, N-alkylated imino analogue of D-glucose. Miglustat competitively and reversibly binds to and inhibits the activity of UDP-glucose ...

medlineplus.gov/druginfo/meds/a604015.html

Apr 15, 2016 ... Miglustat: learn about side effects, dosage, special precautions, and more on MedlinePlus.

www.rxlist.com/zavesca-drug.htm

Zavesca (miglustat capsules, 100 mg) is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first ...

ojrd.biomedcentral.com/articles/10.1186/s13023-015-0240-y

Feb 27, 2015 ... The results of this study suggest that miglustat treatment can improve or stabilize neurological manifestations, at least for a period of time; the ...

www.sciencedirect.com/topics/page/Miglustat

Miglustat is an inhibitor of glucosylceramide synthase that was launched as an oral treatment for mild to moderate type I Gaucher's disease in adult patients for ...

www.accessdata.fda.gov/drugsatfda_docs/label/2010/021348s008lbl.pdf

(miglustat capsules, 100mg) is an inhibitor of the enzyme glucosylceramide ... Miglustat, dosed at 50 and 100 mg in Gaucher patients, exhibits dose proportional.

www.zavesca.com